Raymond James & Associates Has $418,000 Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Raymond James & Associates decreased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,199 shares of the company’s stock after selling 1,346 shares during the quarter. Raymond James & Associates owned 0.06% of Vera Therapeutics worth $418,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in VERA. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Vera Therapeutics in the third quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vera Therapeutics by 27.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,579 shares of the company’s stock valued at $282,000 after buying an additional 4,387 shares during the period. Barclays PLC lifted its stake in Vera Therapeutics by 964.6% in the third quarter. Barclays PLC now owns 71,703 shares of the company’s stock valued at $983,000 after buying an additional 64,968 shares during the period. Amalgamated Bank raised its position in shares of Vera Therapeutics by 26.0% during the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after purchasing an additional 864 shares during the period. Finally, Swiss National Bank acquired a new stake in shares of Vera Therapeutics during the third quarter worth about $668,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 2.5 %

NASDAQ:VERA opened at $39.65 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 7.71 and a current ratio of 7.71. The company has a market cap of $2.16 billion, a PE ratio of -17.31 and a beta of 1.05. Vera Therapeutics, Inc. has a 52-week low of $6.07 and a 52-week high of $50.78. The stock has a 50-day simple moving average of $43.12 and a 200 day simple moving average of $26.95.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 5,714 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the transaction, the senior vice president now directly owns 53,171 shares in the company, valued at $2,126,840. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vera Therapeutics news, SVP Joseph R. Young sold 5,714 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the transaction, the senior vice president now directly owns 53,171 shares in the company, valued at $2,126,840. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Maha Katabi sold 81,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $44.20, for a total value of $3,580,597.80. Following the completion of the transaction, the director now owns 3,547,437 shares of the company’s stock, valued at $156,796,715.40. The disclosure for this sale can be found here. Insiders sold a total of 526,551 shares of company stock worth $21,533,345 over the last ninety days. 21.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Vera Therapeutics in a research report on Monday, January 8th. They set an “overweight” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $56.00 price target on shares of Vera Therapeutics in a research report on Friday, April 5th. Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $29.00 to $37.00 in a research report on Friday, January 26th. Oppenheimer assumed coverage on Vera Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price target on the stock. Finally, Wedbush raised their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a research report on Thursday, March 21st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $32.29.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.